• Viking Therapeutics (NasdaqCM:VKTX) has advanced its obesity drug candidate VK2735 into Phase 3 development following FDA feedback.
• Enrollment for the pivotal subcutaneous Phase 3 trials, VANQUISH-1 and VANQUISH-2, is reported to be nearly complete.
• The company has also started a new maintenance and transition study for the oral version of VK2735, with readouts expected later this year.

Viking Therapeutics focuses on metabolic and endocrine disorders, and VK2735 sits at the center of its obesity pipeline. With multiple large pharma companies also working on weight loss drugs, investors are watching how smaller specialists such as Viking position their programs. The shift in healthcare spending toward obesity treatments has turned late stage clinical progress into a key reference point for many shareholders.

For investors, these new trials help clarify what the potential regulatory path for VK2735 might look like, even though outcomes remain uncertain. The combination of subcutaneous Phase 3 studies and an oral maintenance trial provides additional data points that could influence future partnership discussions, capital needs, and any eventual commercialization strategy if approvals are pursued.

Stay updated on the most important news stories for Viking Therapeutics by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Viking Therapeutics.

Quick Assessment

• ✅ Price vs Analyst Target: At US$35.76 versus a consensus target of about US$92.72, the price sits roughly 61% below analyst expectations.
• ✅ Simply Wall St Valuation: Simply Wall St currently assesses Viking as trading about 87.2% below its estimated fair value.
• ✅ Recent Momentum: The stock has returned about 22.0% over the last 30 days.

There is only one way to know the right time to buy, sell or hold Viking Therapeutics. Head to Simply Wall St's company report for the latest analysis of Viking Therapeutics's Fair Value.

Key Considerations

• 📊 Advancing VK2735 into Phase 3 with enrollment nearly complete makes clinical results a central driver of how investors may reassess Viking at US$35.76.
• 📊 Keep an eye on Phase 3 VK2735 obesity readouts, oral maintenance study data later this year, and any updates to the US$92.72 analyst price target range of US$35 to US$125.
• ⚠️ Viking remains a clinical stage company with US$0 revenue and ongoing losses, so any setback in VK2735 could weigh heavily on the current valuation case.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Viking Therapeutics analysis. Alternatively, you can check out the community page for Viking Therapeutics to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.